BACKGROUND: Intravenous immunoglobulin (IVIg) and corticosteroids are effective as initial treatment in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but little is known about the comparative risk-benefit profile of their long-term use in this disease. We compared the ...
transduction molecules. New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immu...
[human], 10% caprylate/chromatography purified) is indicated for the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older, idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in ...
New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including ...
CIDP, chronic inflammatory demyelinating polyneuropathy;IG, immune globulin;ITP, idiopathic thrombocytopenic purpura;IV, intravenous;PIDD, primary immunodeficiency disease;SCIG/sub Q, subcutaneous immunoglobulin. References Merkies IS, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements...
In conclusion the transition of patients with CIDP who are stable on IVIG therapy to FIT can lead to severe worsening of disease. Further research to understand the immunopathogenesis of this worsening, may shed light as to the appropriate strategy for initiating this switch or may identify unique...
CIDP CIDP=chronic inflammatory demyelinating polyneuropathy; PI=primary immunodeficiency. IMPORTANT SAFETY INFORMATIONincluding BOXED WARNING for Thrombosis INDICATIONS HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older and for ch...
We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients. 展开 关键词: CIDP, inflammatory neuropathies, IVIg, MMN, pump-system, ...
Grifols and the GBS|CIDP Foundation for the study of disease activity biomarkers in CIDP; HL reports grants from the Dutch Prinses Beatrix Spierfonds, during the conduct of the study; HG has received research support from Prinses Beatrix Spierfonds, travel grants and speaker fee from Takeda/Shi...
We identified 8 patients without any treatment for more than 5 years (CIDP Disease Activity Status 1B - CDAS 1B). All 8 patients fulfilled the EFNS/PNS criteria for definite MMN and were stable for a mean period of 14 years (7-20 years). Stability was defined when patients had the ...